

Anti-MMP9 Antibody (Andecaliximab)

Introduction

Andecaliximab is a biopharmaceutical targeting matrix metalloproteinase 9 (Andecaliximab is a recombinant IgG4 monoclonal antibody against MMP9. Andecaliximab has shown anti-fibrotic efficacy in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used in the study of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

Product parameters

Alternative Names	AB0045, GS-5745
Target Accession	P14780
Target	MMP9
CAS number	1518996-49-0
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human MMP9 His at 2 ug/mL can bind Anti-MMP9 Antibody (Andecaliximab), EC50=0.006577 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

